Pa. Newhouse et al., MODELING THE NICOTINIC RECEPTOR LOSS IN DEMENTIA USING THE NICOTINIC ANTAGONIST MECAMYLAMINE - EFFECTS ON HUMAN COGNITIVE-FUNCTIONING, Drug development research, 31(1), 1994, pp. 71-79
The loss of central nicotinic receptors is a neurochemical hallmark of
several degenerative brain disorders, notably Alzheimer's disease (AD
) and Parkinson's disease (PD). However, uncertainty has remained abou
t the significance of this loss for the cognitive symptomatology of th
ese disorders. Symptoms of impaired acquisition of information and sho
rt-term storage, impaired memory consolidation, attention, visual perc
eption, and speed may reflect nicotinic lesions. Administration of the
nicotinic antagonist mecamylamine in young and elderly humans produce
s significant dose-related impairment of new learning, liberalization
of response bias, and slowing of reaction time. These results suggest
that mecamylamine may in part model the results of nicotinic receptor
loss in AD and that nicotinic augmentation of some aspects of cognitiv
e functioning may be a worthwhile strategy to pursue, particularly if
agents can be developed that are more selective than nicotine itself.
(C) 1994 Wiley-Liss, Inc.